Tag: Cerenovus

Cerenovus launches next-generation Cereglide 71 catheter for ischaemic stroke revascularisation

Cerenovus, part of Johnson & Johnson MedTech, has announced the launch of its Cereglide 71 device—a next-generation intermediate catheter with TruCourse technology indicated for...

Striving for more distal guide-catheter placement is a “no-brainer” in stroke...

This advertorial, intended for US readers only, is sponsored by CERENOVUS. “Going distally with guide catheters is more routine nowadays,” says Violiza Inoa (Memphis, USA),...

Combined thrombectomy technique fails to demonstrate superiority over aspiration alone

New data from the VECTOR randomised controlled trial—presented at the European Stroke Organisation Conference (ESOC; 24–26 May, Munich, Germany)—have indicated that a mechanical thrombectomy...

World-renowned clot science drives outstanding EMBOTRAP stent retriever outcomes in MASTRO...

This advertorial is sponsored by CERENOVUS. The EMBOTRAP® family of revascularisation devices (CERENOVUS) is innovative within the stent retriever space due to its differentiated design...
cerepak detachable coils

Cerenovus announces commercial availability of Cerepak detachable coils in USA

Cerenovus has announced that the new Cerepak detachable coils are now commercially available in the USA, and that the first patient cases have been...

The positive clinical impact of a comprehensive, compatible stroke solutions portfolio

This advertorial is sponsored by CERENOVUS. Following the recent addition of the EMBOGUARD balloon guide catheter (BGC) to the CERENOVUS STROKE SOLUTIONSi portfolio of devices,...
cerenovus svin 2022

Cerenovus reveals positive stent-retriever thrombectomy outcomes within EXCELLENT registry

Cerenovus, part of Johnson & Johnson MedTech, has today announced positive primary outcomes from the real-world EXCELLENT registry, focused on stroke-inducing blood clot removal...
cerenovus svin 2022

Cerenovus announces clinical data and product showcases ahead of SNIS 2022

Cerenovus, part of Johnson & Johnson MedTech, will showcase its latest innovations in stroke care at the 2022 Society of NeuroInterventional Surgery (SNIS) annual...

First Emboguard experiences reveal “excellent trackability and ease of use” in...

Having been launched earlier this year, the Emboguard balloon guide catheter (Cerenovus) was recently used in mechanical thrombectomy procedures for the first time. David...

Cerenovus launches Emboguard balloon guide catheter for acute ischaemic stroke

Cerenovus—a neurovascular firm that forms part of Johnson & Johnson Medical Devices Companies—has announced the launch of Emboguard, its next-generation balloon guide catheter to...
cerenovus svin 2022

Cerenovus to unveil new data and showcase stroke care innovations at...

Cerenovus, a neurovascular firm that forms part of The Johnson & Johnson Medical Devices Companies, will showcase its latest innovations in stroke care at...

First-pass success in mechanical thrombectomy lowers costs in treatment of acute...

A recent Cerenovus study published in the Journal of Stroke (JOS) has found that in the treatment of acute ischaemic stroke, achieving complete or near...

Cerenovus unveils new clot extractor device in European launch

  Cerenovus, part of Johnson & Johnson Medical Devices Companies, has today announced the European launch of Cerenovus Nimbus, a device designed to remove tough clots for successful revascularisation in patients...

Advanced engineering improves rates of revascularisation through the first-pass effect

Advertorial In acute ischaemic stroke, fast and complete recanalisation of the occluded vessel is associated with improved outcomes. While morbidity and mortality in these patients...

Cerenovus launches largest global registry to study stroke-inducing blood clots removed...

Johnson & Johnson has announced that its Cerenovus business has launched the single largest global registry, the EXCELLENT Registry, to collect and analyse stroke-inducing...

First intracranial aneurysm patients treated with BRAVO Flow Diverter

Cerenovus, part of the Johnson & Johnson Medical Devices Companies, has announced that the first patients have been treated with the BRAVO Flow Diverter,...

First pass effect…always the goal!

Ischaemic stroke is as quick as it is destructive; minutes, even seconds can be the difference between patients returning to a healthy life or a hindered one....

Cerenovus receives US FDA clearance for next generation stent retriever device...

Cerenovus has announced it has received 510(k) clearance from the US Food and Drug Administration (FDA) for EMBOTRAP II revascularisation device, a next generation...

Cerenovus launches next generation embolic coil for treatment of cerebral aneurysms...

Cerenovus, part of the Johnson & Johnson Medical Devices Companies, has announced the launch of the Galaxy G3 mini coil, its smallest and softest...

Real-life use of EmboTrap shows comparable outcomes to large stroke studies

The real-life use of the EmboTrap device (Neuravi/Cerenovus) has provided “very good outcomes” when compared to that observed in large mechanical thrombectomy trials which...

Cerenovus launches in Europe

Johnson & Johnson Medical Devices Companies introduced Cerenovus, its new neurovascular business, at the European Society of Minimally Invasive Neurological Therapy (ESMINT) 9th Annual...

Cerenovus introduced at SNIS

Johnson & Johnson Medical Devices Companies introduced Cerenovus, its new neurovascular business, at the Society of NeuroInterventional Surgery 14th Annual Meeting (SNIS; 24–28 July,...